10 leading pharma executives you need to know

Pfizer CEO Dr. Albert Bourla [Image courtesy of Pfizer/Business Roundtable]Given the complexity of the pharmaceutical business, it can be challenging to gauge the performance of any chief executive in the space.

That said, CEOs’ annualized return over tenure as CEO over their term can hint at performance. In addition, rating sites like Glassdoor also indicate CEOs’ popularity.

Here, we parsed a range of metrics, including CEOs’ approval ratings, their ability to navigate the pandemic and their firms’ stock performance over time, to identify ten leading pharma executives.

Get the full story from our sister site, Drug Discovery & Development. 

Read more
  • 0

January 2022 Issue: The pandemic tested Medtronic’s mettle


The pandemic tested Medtronic’s mettle: Its CFO explains how

How Abbott seeks to improve care, health inequities for people with cardiovascular disease

Medtech’s biggest personnel changes in 2021

The top 5 medtech news stories of 2021

Some thoughts for medtech leaders in 2022

Starting our third year of the COVID-19 pandemic, I wonder when it will ever end. Four words stick in my head: “This stuff is hard.” (That’s the G-rated version.)

It’s tough when things don’t go your way, but you must learn to accept the situation and persevere. Keep on working at it, and it will eventually get better. As Dylan Thomas wrote in a poem I memorized when I was young: “Do not go gentle into that good night.”

The past year was a lot about aspirations colliding with hard truths. We thought vaccines and masks would beat COVID. The vac…

Read more
  • 0

9 lessons in crisis management from Stryker CEO Kevin Lobo

Decades of corporate leadership helped him address the challenges that 2020 wrought.

Stryker CEO Kevin Lobo

The past year presented extraordinary leadership challenges for CEOs. First came the COVID-19 pandemic, then social unrest following the killing of George Floyd, and finally a contentious election that tore at the political connective tissue of the nation.

The year may have been unique, but Stryker CEO Kevin Lobo said his strategies at the orthopedics giant drew upon upon basic tenets of leadership that he learned leading businesses in first the chemical and then medical device industries. He joined medtech in 2003 when he took a senior post at Johnson & Johnson.

“All crises have similarities,” Lobo told Medical Design & Outsourcing. “Obviously the magnitude of this is unprecedented. I’ve never been through anything like this, but I’d been through other crises before.”

(Listen to the DeviceTalks Weekly interview with Lobo.) 


Read more
  • 0